BTIG Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)

BTIG analyst Julian Harrison reiterated a Buy rating and $55.00 price target on Tvardi Therapeutics Inc (NASDAQ: TVRD).

The analyst comments "The Phase 2 trial of TTI-101 in IPF is now fully enrolled, firming up timeline to 12wk data expected in 4Q25 (previously guided to 2H25). IPF represents a ~$5B market today comprised of two advanced therapies that only slow functional decline and have high discontinuation rates (>40%). We believe TTI-101 could be confirmed as the first Tx option in IPF that actually reverses patients out of disease, instead of just slowing decline. On this point, we continue to see a unique potential for positive readthrough from blinded interim FVC results to topline data in the Phase 2 trial as positive FVC changes are almost never seen in untreated IPF patients and rarely seen with current SoC (detailed analysis below). In addition, we expect TTI-101's differentiated mechanism to avoid intolerable safety AEs. We also see scarcity value in TTI-101 as the only STAT3 inhibitor we are aware of in development for IPF in the US and expect increased strength in the stock as appreciation for TTI-101's potential in IPF grows ahead of Phase 2 data. Reiterate BUY."

For an analyst ratings summary and ratings history on Tvardi Therapeutics Inc click here. For more ratings news on Tvardi Therapeutics Inc click here.

Shares of Tvardi Therapeutics Inc closed at $33.39 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
• Citi Downgrades Petroreconcavo SA (RECV3:BZ) to Neutral
• UBS Downgrades Lojas Renner SA (LREN3:BZ) (LRENY) to Neutral